Cooley advised NeuExcell Therapeutics on the deal. NeuExcell Therapeutics, a neurodegenerative disease gene therapy company, announced its $15 million+ Series Pre-A+ financing round. Investors in the round...
Cooley advised NeuExcell Therapeutics on the deal. NeuExcell Therapeutics, a neurodegenerative disease gene therapy company, announced its $15 million+ Series Pre-A+ financing round. Investors in the round...
You must be a Standard 1 Year member to access this content.